Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$84.32

-1.08 (-1.26%)

17:08
10/19/16
10/19
17:08
10/19/16
17:08

BioMarin reports Phase 2 vosoritide data in dwarfism

BioMarin provided an update on its Phase 2 study of vosoritide in children with achondroplasia, the most common form of dwarfism, at the American Society of Human Genetics 2016 Meeting. Results from 8 children in cohort 4, who completed six months of daily dosing at 30 microgram/kg/daily experienced a 46% or 2.1 cm/year increase in mean annualized growth velocity from baseline. These data are comparable to those observed at the lower dose of 15 microg/kg/day in cohort 3, the company said. Results from 10 children in cohort 3, who completed six months of daily dosing at 15 microgram/kg/day experienced a 50% or 2.0 cm/year increase in mean annualized growth velocity from baseline. Vosoritide was generally well tolerated at all doses. All injection site reaction events were mild and transient. No new safety findings were observed at the 30 microg/kg/day dose. "The data support our use of the lower dose of 15 microgram/kg/day in the Phase 3 study," the company said, adding that "the company believes based on discussions with global health authorities that change in growth velocity from baseline as an endpoint could lead to registration. The company plans to augment these data with supportive evidence concerning proportionality and functionality."

  • 19

    Oct

  • 27

    Oct

  • 06

    Nov

  • 29

    Nov

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

BMRN BioMarin
$84.32

-1.08 (-1.26%)

09/21/16
LEER
09/21/16
NO CHANGE
LEER
Market Perform
Previous PTAB ruling remains overhang on Sarepta eteplirsen, says Leerink
Leerink analyst Joseph Schwartz notes that Sarepta (SRPT) has announced favorable Patent Trial and Appeal Board of the U.S. Patent and Trademark Office decisions in favor of its exon 51 and 53 composition of matter patent interference cases against BioMarin (BMRN). However, he points out that these rulings are subject to appeal and a previous ruling from the U.S. Patent Trial and Appeal Board, or PTAB, in favor of BioMarin's method of use patent remains an overhang on the commercialization of Sarepta's eteplirsen. The analyst reiterates a Market Perform rating on Sarepta's shares.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/14/16
BARD
10/14/16
NO CHANGE
Target $115
BARD
Outperform
BioMarin hemophilia drug update encouraging, says Baird
Baird analyst Michale Ulz said he is encouraged by BioMarin's update on its Phase 1/2 study of its Hemophilia A drug, BMN-270. The analyst noted U.K. regulators approved continued enrollment in the gene-therapy study and the study was amended to allow dose optimization ahead of the Phase 2b study expected in 2017. Ulz reiterated his Outperform rating and $115 price target on BioMarin shares.
10/17/16
JANY
10/17/16
NO CHANGE
JANY
PTC's denial has negative read-through for BioMarin, says Janney Capital
Janney Capital noted that PTC Therapeutics' (PTCT) Translarna and Sarepta's (SRPT) Exondys 51 address non-overlapping DMD populations and there was an expectation of flexibility from the FDA following the conditional approval of Exondys 51. However, the FDA has denied the first appeal of the refuse to file letter regarding PTC's NDA for Translarna for the treatment of nonsense mutation DMD, which the firm said has potential negative read-through for BioMarin's (BMRN) attempt to rekindle Kyndrisa, which is a direct competitor to Sarepta's Exondys 51. The firm added that the news might positively impact reimbursement decisions for Exondys 51.

TODAY'S FREE FLY STORIES

AAPL

Apple

$176.04

-0.16 (-0.09%)

13:22
01/17/18
01/17
13:22
01/17/18
13:22
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple sees creating over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

AAPL

Apple

$176.19

-0.9 (-0.51%)

13:21
01/17/18
01/17
13:21
01/17/18
13:21
Hot Stocks
Apple to announce new U.S. campus location later this year »

Apple in its statement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

ICHR

Ichor Holdings

$25.60

0.86 (3.48%)

13:18
01/17/18
01/17
13:18
01/17/18
13:18
Recommendations
Ichor Holdings analyst commentary  »

Ichor Holdings price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 07

    Feb

IPSEY

Ipsen

13:18
01/17/18
01/17
13:18
01/17/18
13:18
Hot Stocks
Ipsen: Onivyde+-FU/LV improved overall survival in Phase 3 study »

Ipsen Biopharmaceuticals,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

$NSD

NASDAQ Market Internals

13:17
01/17/18
01/17
13:17
01/17/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
01/17/18
01/17
13:16
01/17/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$63.42

0.92 (1.47%)

13:15
01/17/18
01/17
13:15
01/17/18
13:15
Hot Stocks
Wells Fargo announces retirement of chief risk officer Mike Loughlin »

Wells Fargo & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACLS

Axcelis

$30.30

1.15 (3.95%)

, AMAT

Applied Materials

$54.50

1.05 (1.96%)

13:14
01/17/18
01/17
13:14
01/17/18
13:14
Recommendations
Axcelis, Applied Materials analyst commentary  »

Axcelis presentation an…

ACLS

Axcelis

$30.30

1.15 (3.95%)

AMAT

Applied Materials

$54.50

1.05 (1.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

AVGO

Broadcom

$263.25

-1.04 (-0.39%)

13:12
01/17/18
01/17
13:12
01/17/18
13:12
Periodicals
Broadcom probed by FTC over negotiations with customers, WSJ reports »

The FTC is probing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLM

Sallie Mae

$11.47

-0.24 (-2.05%)

13:08
01/17/18
01/17
13:08
01/17/18
13:08
Technical Analysis
Technical Earnings Preview: SLM Corp in middle of range before news »

Shares have been trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AAPL

Apple

$176.19

-0.9 (-0.51%)

13:08
01/17/18
01/17
13:08
01/17/18
13:08
Hot Stocks
Apple announces new U.S. investments, sees $38B of repatriation taxes »

Apple announced a new set…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

13:05
01/17/18
01/17
13:05
01/17/18
13:05
General news
Treasury Action: early March bills continue to underperform »

Treasury Action: early…

FOX

21st Century Fox

$35.79

-0.58 (-1.59%)

, FOXA

21st Century Fox

$36.29

-0.44 (-1.20%)

13:04
01/17/18
01/17
13:04
01/17/18
13:04
Periodicals
FoxNext acquires game developer Cold Iron Studios, Polygon says »

FoxNext Games, the video…

FOX

21st Century Fox

$35.79

-0.58 (-1.59%)

FOXA

21st Century Fox

$36.29

-0.44 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 07

    Feb

  • 07

    Feb

AAPL

Apple

$176.19

-0.9 (-0.51%)

13:02
01/17/18
01/17
13:02
01/17/18
13:02
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple breaking ground…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

AAPL

Apple

$176.19

-0.9 (-0.51%)

13:01
01/17/18
01/17
13:01
01/17/18
13:01
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple sees investing over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

AAPL

Apple

$176.19

-0.9 (-0.51%)

13:01
01/17/18
01/17
13:01
01/17/18
13:01
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple announces new set…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

UPS

UPS

$133.62

0.74 (0.56%)

13:00
01/17/18
01/17
13:00
01/17/18
13:00
Options
Notable call spread in UPS as shares deliver profits »

Notable call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AA

Alcoa

$56.35

0.11 (0.20%)

12:57
01/17/18
01/17
12:57
01/17/18
12:57
Technical Analysis
Technical Earnings Preview: Alcoa near 52-week high before news »

Ahead of earnings, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

AAPL

Apple

$176.19

-0.9 (-0.51%)

, BMWYY

BMW

$37.64

1.125 (3.08%)

12:51
01/17/18
01/17
12:51
01/17/18
12:51
Periodicals
BMW to offer CarPlay as subscription-based service next year, The Verge says »

BMW (BMWYY) plans to…

AAPL

Apple

$176.19

-0.9 (-0.51%)

BMWYY

BMW

$37.64

1.125 (3.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

TBT

ProShares UltraShort 20+ yr Trsry

$34.72

-0.06 (-0.17%)

12:50
01/17/18
01/17
12:50
01/17/18
12:50
Options
Closing puts in the ProShares UltraShort Longer-term Bond ETF »

Closing puts in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:50
01/17/18
01/17
12:50
01/17/18
12:50
General news
U.S. equities extended their bounce »

U.S. equities extended…

ERJ

Embraer

$24.67

-0.1125 (-0.45%)

, BA

Boeing

$347.06

11.9016 (3.55%)

12:48
01/17/18
01/17
12:48
01/17/18
12:48
Periodicals
Embraer tells Bloomberg no guarantee Boeing talks with result in deal »

Embraer (ERJ), in an…

ERJ

Embraer

$24.67

-0.1125 (-0.45%)

BA

Boeing

$347.06

11.9016 (3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

ASML

ASML

$186.38

5.51 (3.05%)

, LRCX

Lam Research

$190.39

1.88 (1.00%)

12:46
01/17/18
01/17
12:46
01/17/18
12:46
Hot Stocks
ASML results pull semiconductor equipment maker shares higher »

Shares of semiconductor…

ASML

ASML

$186.38

5.51 (3.05%)

LRCX

Lam Research

$190.39

1.88 (1.00%)

KLAC

KLA-Tencor

$107.66

0.37 (0.34%)

AMAT

Applied Materials

$54.50

1.05 (1.96%)

TER

Teradyne

$46.51

1.2 (2.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

BCS

Barclays

$11.01

0.045 (0.41%)

12:45
01/17/18
01/17
12:45
01/17/18
12:45
Periodicals
Barclays slashes up to 100 senior investment bank staff, Bloomberg says »

Barclays is cutting up to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMI

Kinder Morgan

12:41
01/17/18
01/17
12:41
01/17/18
12:41
Technical Analysis
Technical Earnings Preview: Kinder Morgan in uptrend before results »

The stock has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.